STM-02: Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing Insulin-like Growth Factor Receptor 1 (IGF-1R)
Phase of Trial: Phase I
Latest Information Update: 23 Aug 2019
Price : $35 *
At a glance
- Drugs IGF-methotrexate (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms STM-02
- 31 Aug 2018 Biomarkers information updated
- 27 Apr 2017 Status changed from recruiting to completed.
- 01 Jun 2014 The study design presented at : 50th Annual Meeting of the American Society of Clinical Oncology.